Why Nanobiotix Shares Plummeted
- Nanobiotix shares are trading lower after the company raised going concerns in its Q4 earnings release.
- The company noted net losses of €57.0 million in 2022 and a net decrease in cash and cash equivalents of €42.5 million in 2022.
- On December 31, 2022, the accumulated deficit was €227.3 million, and the negative working capital was €22.7 million.
- Nanobiotix expects to continue to incur significant expenses related to developing and manufacturing nanotechnology product candidates such as NBTXR3 and conducting clinical studies.
- The company also noted that the EIB loan contains covenants that require maintenance of minimum cash & cash equivalent balances, sufficient to fund till Q3 FY23, that limit the availability of cash resources to pursue operational needs.
- Reported €41.4 million in cash and cash equivalents as of December 31, 2022.
- Nanobiotix has obtained a €15 million temporary waiver until July 31, 2023, and has agreed with the EIB to automatically extend it until January 31, 2024, should a business development partnership, collaborative or strategic alliance have become effective before July 31, 2023.
- The company is also pursuing additional funding through one or more possible new partnerships, collaborative or strategic alliances.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.